Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease
NCT ID: NCT00679692
Last Updated: 2008-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
210 participants
OBSERVATIONAL
2006-09-30
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
METHODS The subjects in the present study included 60 healthy controls, 30 hepatitis patients, 60 liver cirrhosis patients and 60 untreated hepatocellular carcinoma patients. Blood was drawn by venipuncture into Venoject tubes. To find the possible correlations between liver damage and IGFs, serum IGF-1, GH, IGFBP-3 concentration and related biochemical parameters were measured. We used immunoradiometric assay to determine the levels of IGF-1, HGH and IGFBP-3 in serum.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tumor Growth Factors in Hepatocellular Carcinoma
NCT00764140
Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma
NCT00769535
Liver Fibrosis in Peri-menopausal Women
NCT03602573
Polymorphisms of Fibrosis-Relating Genes on Outcome of HCV-Related Chronic Liver Disease
NCT00629603
To Study the Effects of Host Genetic Factors on Liver Cirrhosis and Hepatocellular Carcinoma (HCC)
NCT00709085
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
3:
three arms for study
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be primary Hepatocellular carcinoma and untreament
Exclusion Criteria
30 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kaohsiung Medical University Chung-Ho Memorial Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kaoshing Medical University Chung-Ho Memorial Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
chiou m Lin, Ms
Role: PRINCIPAL_INVESTIGATOR
Kaohsiung Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Radio immunoassay lab,Department of Nuclear Medical University Hospital,No.100 Tzyou 1st Road
Kaohsiung City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KMUH-IRB-950123
Identifier Type: -
Identifier Source: secondary_id
KMUH-IRB-950123
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.